The FDA delays a decision on Salix's (SLXP) crofelemer drug for treating HIV-related diarrhea,...

|About: Salix Pharmaceuticals, Ltd. (SLXP)|By:, SA News Editor

The FDA delays a decision on Salix's (SLXP) crofelemer drug for treating HIV-related diarrhea, with a ruling now expected by the end of Q1 2013. Talks between Salix and the FDA are focusing on the production and control of the crofelemer active pharmaceutical ingredient. Episodic or chronic diarrhea affects ~40% of the U.S.'s 1.2M HIV/AIDS sufferers.